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Abstract
Purpose: To investigate the association between dose to various anatomical structures and
dysphagia among patients with head and neck cancer treated by definitive intensity-modulated
radiotherapy (IMRT) and concurrent chemotherapy.
Methods and materials: Thirty-nine patients with squamous cancer of the head and neck were
treated by definitive concurrent chemotherapy and IMRT to a median dose of 70 Gy (range, 68 to
72). In each patient, a gastrostomy tube (GT) was prophylacticly placed prior to starting treatment.
Prolonged GT dependence was defined as exceeding the median GT duration of 192 days.
Dysphagia was scored using standardized quality-of-life instruments. Dose-volume histogram
(DVH) data incorporating the superior/middle pharyngeal constrictors (SMPC), inferior pharyngeal
constrictor (IPC), cricoid pharyngeal inlet (CPI), and cervical esophagus (CE) were analyzed in
relation to prolonged GT dependence, dysphagia, and weight loss.
Results: At 3 months and 6 months after treatment, 87% and 44% of patients, respectively, were
GT dependent. Spearman's ρ analysis identified statistical correlations (p < 0.05) between
prolonged GT dependence or high grade dysphagia with IPC V65, IPC V60, IPC Dmean, and CPI
Dmax. Logistic regression model showed that IPC V65 > 30%, IPC V60 > 60%, IPC Dmean > 60
Gy, and CPI Dmax > 62 Gy predicted for greater than 50% probability of prolonged GT
dependence.
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Conclusion: Our analysis suggests that adhering to the following parameters may decrease the
risk of prolonged GT dependence and dysphagia: IPC V65 < 15%, IPC V60 < 40%, IPC Dmean < 55
Gy, and CPI Dmax < 60 Gy.
Introduction
Concurrent chemoradiation therapy using intensity-mod-
ulated radiotherapy (IMRT) has gained widespread
acceptance as a definitive treatment for locally advanced
head and neck cancer due to significant improvement in
tumor control and organ preservation with the addition
of chemotherapy, and promising advantage of increasing
therapeutic gain using IMRT technique [1-4]. However, it
is becoming increasingly clear that chemoradiation strat-
egy is associated with an increased incidence and severity
of swallowing-related toxicities, including high-grade dys-
phagia, severe weight loss, and prolonged dependence on
gastrostomy tube (GT) for fluid and nutritional support
[5-7].
Indwelling GT has been shown to compromise quality of
life because it may cause infection and physical discom-
fort, distort patient's self-esteem, and induce anxiety,
depression, and social isolation [8]. Presently there is a
lack of data associating GT dependence and dosimetric
parameters among patients undergoing definitive chemo-
radiotherapy using IMRT for head and neck cancer [9,10].
This is of practical significance since, as a result of IMRT
optimization, radiation doses can potentially be
"dumped" to unspecified anatomical areas including
those related to dysphagia that have not yet been rigor-
ously investigated [11]. In a prospective trial using IMRT,
Feng et al demonstrated the importance of monitoring
dose to the pharyngeal constrictor muscles, the cervical
esophagus (CE), and the glottic and supraglottic larynx
(GSL) [12]. The purpose of the present study was to inves-
tigate the potential association between radiation dose to
these structures vital for swallowing and severity of dys-
phagia, notably prolonged GT dependence, among a
cohort of patients undergoing definitive IMRT chemoradi-
ation for locally advanced head and neck cancer.
Methods and materials
Patient characteristics
This was a retrospective study approved by the Institu-
tional Review Board at the University of California, Davis
(UCD). Between January 2003 and January 2007, forty-
eight patients with newly diagnosed squamous cell carci-
noma involving the oral cavity, oropharynx, larynx or
hypopharynx were treated with definitive chemoradiation
consisting of IMRT and cisplatin at the UCD Cancer
Center. Seven patients who either developed locoregional
recurrence or were lost during follow up were excluded
from the study. Two patients who refused prophylactic
placement of a GT were also excluded. The remaining 39
patients included in the study. The median follow up was
15.6 months (range, 4.5 to 52 months), with 27 patients
followed greater than 1 year. All patients received prophy-
lactic placement of a GT prior to starting treatment. The
GT was subsequently removed upon resolution of high
grade dysphagia and stabilization of weight after treat-
ment. Physician judgment if GT needed to be maintained
was based on the criteria that 1) the patient's weight could
not be maintained with less than two cans of supplemen-
tal feeding per day, or 2) the patient could not tolerate
solid food without complaints of dysphagia,
Table 1: Patient and tumor characteristics.
Variable No. patients %
Age Mean 56,
Continuous range 32-77
Gender
Male 32 82
Female 7 18
Active smoking*
Yes 30 77
No 9 13
Alcohol use
Heavy** 11 28
Others 28 72
KPS
80-100 25 64
60-70 14 36
Primary site
Oral cavity 2 5
Oropharynx 25 64
Larynx 6 15
Hypopharynx 3 8
Unknown primary 3 8
T stage
T0, 1, 2 25 64
T3, 4 14 36
N stage
N0/N1 16 41
N2 19 49
N3 4 10
Chemo regimen
CDDP-based 33 85
Others 6 15
Post RT neck dissection
Yes 5 13%
No 34 87%
*: currently smoking or smoking history within one year.
**: self reported active heavy alcohol drinking or more than one 6-
pack of beers per day.Radiation Oncology 2009, 4:52 http://www.ro-journal.com/content/4/1/52
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odynophagia or aspiration. None of the patients required
GT reinsertion once the GT was initially removed after
completion of radiation therapy. Table 1 shows patient
characteristics of the study population.
Target volume delineation
The gross tumor volume (GTV) was specified as the gross
extent of tumor as demonstrated by preoperative imaging
and physical examination including endoscopy. Grossly
positive lymph nodes were defined as any lymph nodes
greater than 1 cm or those with a necrotic center. The
high-risk clinical target volume (CTV1) was defined as the
GTV plus a margin of 1-2 cm to account for microscopic
disease spread. The CTV2 generally included the prophy-
lactically treated cervical and supraclavicular neck. A CTV3
was also created to designate an area at lowest risk within
the prophylactically treated low neck. The low neck was
encompassed within the IMRT plan in all cases, and thus
a separate anterior low-neck field was not used. Depend-
ing on disease site, the planning target volume (PTV) con-
tained an automated 0.5 cm expansion of the CTV
surfaces to account for patient setup error to create PTV1,
PTV2, and PTV3, if necessary. The tumor volumes and sen-
sitive normal structures were delineated on serial treat-
ment planning CT images. Structures considered to be
critically at risk included the spinal cord, optic nerves,
optic chiasm, orbits, lens, brainstem, and parotid glands.
No overlap between CTVs and uninvolved critical adja-
cent tissues was permitted for optimization purposes.
Dose specification
For patients receiving definitive radiation therapy, treat-
ment plans were designed to provide a dose of 68 to 72 Gy
(median, 70 Gy) to 95% or greater of the PTV1 while spar-
ing neighboring critical structures. The prescribed dose to
PTV3 was 54 to 56 Gy. Dose to PTV2 ranged from 59.4 to
63 Gy (median, 60 Gy). For critical normal structures,
dose constraints were designed to limit the maximum
dose, whenever possible, to 1% of the volume to 54 Gy for
the brainstem and optic nerves, 45 Gy for the spinal cord
and optic chiasm, 60 Gy for the temporal lobes, and 30 Gy
to 50% of the contralateral parotid gland. Treatment was
by continuous-course IMRT with once-a-day treatment.
Because our goal was to prescribe 1.8 Gy per fraction to
the PTV2 daily, the PTV1 received a higher dose per frac-
tion, typically 2.0 Gy or 2.12 Gy per fraction, and PTV3
typically 1.6-1.7 Gy per fraction.
Delineation of swallowing structures
The IMRT treatment plans of all 39 patients treated by
definitive chemoradiation were retrieved from archival
records. With the help of a board-certified head and neck
surgeon, the swallowing structures were contoured on
axial CT slides as previously described [11-14] (Fig. 1).
Briefly, the pharyngeal constrictor (PC) was outlined as a
single structure for which the cranial-most extent was the
caudal tips of the pterygoid plates and the caudal-most
extent was the inferior border of the cricoid cartilage. For
purposes of analysis, the constrictors were considered as
one structure and were also schematically divided into
two parts: the superior and middle PC (SMPC) was
defined from the caudal tips of the pterygoid plates
through the lower edge of the hyoid, at the level of C2, C3
and upper C4. The inferior PC (IPC) was defined from
below the hyoid through the inferior edge of the cricoid,
with attachment to the inferior horn of thyroid cartilage,
at the level of lower C4, C5 and upper C6. On non-con-
trast CT images, IPC can be identified as a structure with
faint enhancement of mucosa surrounded by a thin intra-
mural fat plate which facilitates the exclusion of the pos-
terior cricoarytenoid muscle. The cricopharyngeal inlet
(CPI) was defined as an oval structure of 1 cm in length,
with lack of intramural fat plate. It extends from the cau-
dal cricoid to the first tracheal ring, and is located at the
level of lower C6. The CE was contoured as a round struc-
ture, caudal to the CPI, with its caudal-most extent corre-
sponding to the thoracic inlet. With the above structures
delineated on the axial CT slices, tabular differential dose-
volume histogram (DVH) data for all the structures were
re-computed, taking into consideration the dose actually
delivered.
Chemotherapy regimens
The majority (85%) of the patients received bolus cispla-
tin (100 mg/m2) given every 3 weeks on days 1 and 22.
The remaining patients received either weekly carboplatin
(AUC = 2) or weekly paclitaxel (50 mg/m2) for 6 weeks.
Cetuximab was not used among any of the patients in the
Delineation of the swallowing structures on axial slices from  simulation CT and 3D reconstructed image Figure 1
Delineation of the swallowing structures on axial 
slices from simulation CT and 3D reconstructed 
image. SMPC = superior and middle pharyngeal constrictor; 
IPC = inferior pharyngeal constrictors; CPI = cricoid pharyn-
geal inlet; and CE = cervical esophagus.Radiation Oncology 2009, 4:52 http://www.ro-journal.com/content/4/1/52
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study. None of the patients received sequential induction
or consolidation therapy.
GT management
The GT was inserted by the Department of Interventional
Radiology at UCD, and was changed every three months.
In 3 patients (8%), additional GT changes were performed
due to complications such as infection or obstruction.
Patients were encouraged to undergo feeding by mouth
for as long as it was tolerable. Body weight and toxicity
(dysphagia, xerostomia, mucositis, nausea, vomiting,
constipation, diarrhea, dysguesia, difficulties chewing)
were assessed and addressed with patients weekly. We
used the American Dietetic Association Medical Nutrition
Therapy (MNT) Protocol for Cancer (Radiation Oncol-
ogy) and the UCD Enteral Nutrition Guidelines. Deci-
sions to wean off enteral feeds were based on individual
patient and chemoradiation-induced toxicities with spe-
cific emphasis placed on inability to consume adequate
oral nutrition and fluid, dysphagia, and prevent uncon-
trolled involuntary weight loss. Patients were weaned off
enteral nutrition support when 1) the patient's weight
could be maintained with less than two cans of supple-
mental feed per day, and 2) the patient could have certain
solid food without complaints of dysphagia,
odynophagia or aspiration.
Follow-up evaluation
Patients were typically seen 2 to 3 weeks after completion
of radiation therapy and then every 3 months thereafter
for the first year, every 6 months for the second and third
year, and then annually. The mean follow up time was
16.2 months (range 4.5-52 months). If a persistent neck
node was found on physical examination after comple-
tion of IMRT and/or was positive on PET/CT at 2 months
follow-up, salvage neck dissection was performed. Dura-
tion of GT was defined as the interval between RT comple-
tion and the date of its removal, or until the date of last
follow-up or death if the GT was still present. Prolonged
GT dependence was defined as GT more than the median
GT duration. Two patients whose follow-up time were less
than the mean GT duration were excluded from further
analysis of clinical-dosimetric association. Body weight
and patient-reported dysphagia were recorded during
each follow up. The lowest body weight during the follow
up period was used. Severe weight loss was defined as
more than 15% weight loss. Patient-reported dysphagia
was assessed with the validated UWQOL questionnaires
given to patients during each follow-up visit. It contained
one swallowing question with five possible answers ("I
swallow normally", (grade 0); "I cannot swallow certain
solid food", (grade 1); "I can only swallow soft food",
(grade 2); "I can only swallow liquid food", (grade 3); and
"I cannot swallow", (grade 4). Grade 3 and grade 4
defined high grade dysphagia. Mucositis and xerostomia
was evaluated weekly during treatment, and at follow-up,
based on Common Terminology Criteria for Advanced
Events (CTCAE), version 2.0. Accordingly, high grade
mucositis was defined as confluent pseudomembranous
reaction with continuous patches > 1.5 cm (grade 3) or
necrosis or deep ulceration; this may include bleeding not
induced by minor trauma or abrasion (grade 4).
Transnasal esophagoscopy (TNE), flexible endoscopic 
evaluation of swallow (FEES), and aspiration pneumonia 
work up
Patients with grade 2 or greater dysphagia beyond 3
months after radiation were referred for TNE. The TNE
technique has previously been described [15,16]. At the
discretion of the physician, a FEES or aspiration pneumo-
nia work up (bacterial culture and chest X-ray) was per-
formed. FEES allows direct visual assessment of many
swallowing functions including muscular function, pre-
mature spillage, pooling, laryngeal penetration, and pres-
ence of aspiration. In brief, the patients were examined
seated upright without anesthesia. Liquid (colored water),
pureed food (yogurt), and chewable food (bread) were
ingested while the hypopharynx and laryngeal contents
were viewed with the fiberscope. The results were scored
as "little", "moderate", or "severe" using the following var-
iables: residue, penetration, and aspiration of three differ-
ent types of diet (water, yogurt, and bread), and mucus
stases. Aspiration pneumonia was defined as cultured bac-
terial pneumonia with radiographic evidence of infiltra-
tion.
Statistical analysis
Data analysis and graphs were completed using the R soft-
ware program (R Development Core Team, 2006; R Foun-
dation for Statistical Computing, Vienna, Austria).
Spearman's ρ and univariate regression were used to cal-
culate the correlation of each of these identified DVH
parameters and individual dependent binary variable
(absence or presence of prolonged GT days, grade 3+ dys-
phagia, and severe weight loss). A logistic model, p = 1/
{1+exp [-(α +β *dose or volume of structure)]}, was used
to calculate the probability of developing prolonged GT
days, grade 3+ dysphagia, or severe weight loss. The
unknown parameters α and β were estimated with the
maximum likelihood method. A test was also performed
whether the hypothesis β = 0 can be rejected. A p value of
< 0.05 was interpreted as being statistically significant
from zero. Confidence intervals (95%) were determined.
Multivariate regression was not used due to the model
instability caused by co-linearity between DVH parame-
ters (V40, V50, V60, V65, Dmax, Dmean). Wilcoxon rank-
sum analysis was preformed to identify DVH parameters
that statistically correlated with esophageal stricture.Radiation Oncology 2009, 4:52 http://www.ro-journal.com/content/4/1/52
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Results
Swallowing outcomes after treatment
At 3 months and 6 months after treatment, 87% and 44%
of patients, respectively, were GT dependent (Table 2).
The results of physician-assessed high grade dysphagia
were consistent with that of GT dependence, given that
majority of high grade dysphagia patients were grade 3
with GT dependence. Due to data redundancy, results of
observer-assessed high grade dysphagia were not
reported. Using the UWQOL instrument, 17 patients
(44%) reported high grade dysphagia at any point during
or after treatment. The median percent of maximum
weight loss was 12% (range, -4% to 21%).
More than half (54%) of the patients had Grade 3 or 4
mucositis at some point after radiation, with 23% and 5%
having severe mucositis at 3-month and 6-month follow
up evaluation respectively (Table 2). However, GT
dependence did not improve as rapidly and still persisted
in 87% and 44% of patients at 3 months and 6 months,
respectively. There was a lack of temporal association
between high grade mucositis and prolonged GT depend-
ence of more than 192 days on statistical analysis (p >
0.05). Grade 2 or higher xerostomia was found in 43%
and 36% at 3-month and 6-month follow up evaluation
respectively, and persisted in 31% at the last follow-up
(Table 2).
Twelve of the patients with high grade dysphagia under-
went TNE. Five of them developed stricture at the upper
esophageal sphincter at the level of the cricopharyngeus
muscle, including one with complete luminal stenosis. All
of them underwent dilatation at the time of TNE to relieve
any physical obstruction. Four out of the seven patients
who underwent FEES had finding of moderate or severe
aspiration to one of the diets. Eight patients had aspira-
tion pneumonia work up, and only one of them was diag-
nosed.
The clinical factors listed in Table 1 were included in both
univariate and multivariate analysis of prolonged GT
dependence. Smoking (active smoking or smoking history
within one year) was identified as the only significant fac-
tor predictive for prolonged GT dependence (p = 0.03).
Other clinical factors, including age, gender, history of
alcohol use, KPS, tumor site, T stage, N stage, and type of
chemotherapy regime are not associated with prolonged
GT dependence. Similar analysis of high grade dysphagia
revealed active smoking (p = 0.03) and T stage (p = 0.04)
as significant factors. No other predisposing parameter
was found to be statistically significant. In terms of severe
weight loss, no predisposing parameter was identified to
be statistically significant (data not shown). A total of 5
patients underwent post-treatment neck dissection. Both
univariate and multivariate analysis did not reveal neck
dissection as a significant factor for prolonged GT depend-
ence, high grade dysphagia, or severe weight loss.
DVH analysis for prolonged GT dependence
The DVH parameters for all the swallowing structures
(SMPC, IPC, CPI, and CE) were listed in Table 3. Signifi-
cant factors (p < 0.05) for prolonged GT dependence were
revealed using Spearman's ρ test and subsequent univari-
ate logistic regression in an attempt to identify dose-vol-
ume effect for GT duration longer than 192 days versus
less than 192 days. These factors are IPC V65 (p = 0.003),
IPC V60 (p = 0.002), IPC V50 (p = 0.042), IPC Dmean (p
= 0.016), and CPI Dmax (p = 0.011). CPI V60 has p value
of 0.050. DVH analysis was also performed on a com-
bined structure (IPC, CPI and CE). No statistically signifi-
cant factor was identified (p > 0.05).
The results of dose-response relationships and volume-
response relationships for prolonged GT dependence are
presented in Fig. 2. IPC V65 more than 30%, IPC V60
more than 60%, IPC Dmean more than 60 Gy, and CPI
Dmax more than 62 Gy predicted for a greater than 50%
probability of developing prolonged GT dependence. For
IPC V50, the dose/volume-response relationships results
were not clinically meaningful.
In view of the strong dosimetric-clinical correlations for
CPI and IPC, we repeated the above analysis with exclu-
sion of three patients whose primary disease overlapped
with the relevant structures (CPI and IPC). The same DVH
parameters were observed as significant factors for pro-
longed GT dependence.
DVH analysis for high grade dysphagia, severe weight loss, 
and stricture
Spearman's  ρ test and subsequent univariate logistic
regression analysis revealed significant associations
between several dosimetric parameters and grade 3+
patient-reported dysphagia. These factors are IPC V65 (p =
0.040), CPI Dmax (p = 0.037), and CPI V60 (p = 0.046).
Further analysis of dose-response relationships and vol-
ume-response relationships revealed that IPC V65 more
Table 2: Toxicity after treatment
3 month (%) 6 month (%)
GT dependence 87% 44%
Self-reported dysphagia grade   3 33% 21%
Mucositis
grade   3
23% 5%
Xerostomia grade   2 43% 36%
Abbreviation: GT = gastrostomy tubeRadiation Oncology 2009, 4:52 http://www.ro-journal.com/content/4/1/52
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than 65%, CPI V60 more than 78%, CPI Dmax more than
70 Gy were associated with more than 50% probability of
developing high grade dysphagia. Similar analysis did not
reveal statistically significant DVH predictors for severe
weight loss (data not shown). Wilcoxon rank-sum analy-
sis revealed significant associations between stricture and
two dosimetric parameters (CPI V65, CPI Dmax).
Discussion
It has been a common observation that a correlation exists
between dysphagia and radiation doses to the anatomic
structures responsible for swallowing in patients undergo-
ing definitive chemoradiation for head and neck cancer.
However, the present study is the first to document a rela-
tionship between various dosimetric parameters and pro-
longed GT dependence. Notably, we were able to identify
DVH parameters which were significantly associated with
prolonged GT dependence, including V65 of the IPC, V60
of the IPC, mean dose to the IPC, and maximum dose to
the CPI. Based on these dose/volume-response relation-
ships, we currently recommend IPC V65 less than 15%,
IPC V60 less than 40%, IPC Dmean less than 55 Gy, and
CPI Dmax less than 60 Gy as potentially important DVH
constraints to guide IMRT planning in an attempt to sig-
nificantly reduce the risk of swallowing dysfunction and
prolonged GT dependence.
Our findings demonstrate the importance of IPC and CPI
dosimetric parameters for developing swallowing dys-
function and are consistent with those from several
recently published studies. Caglar et al showed that a
mean dose to the IPC of more than 54 Gy and IPC V50 of
more than 50% were the most significant predictors for
aspiration or stricture development [17]. Levendag et al
identified dose-response relationship between dysphagia
for solids (p < 0.02) or aspiration episodes (p < 0.02) and
mean dose to IPC. A mean dose of 33 Gy to IPC was esti-
mated as the threshold for 20% risk of dysphagia for sol-
ids [14]. Furthermore, Dornfeld et al reported that a more
restrictive diet one year after treatment is significantly cor-
related with higher average dose delivered to the constric-
tor muscles (lateral pharygeal wall) at the level of false
vocal cord [18]. Jensen et al demonstrated that dose above
60 Gy to the upper esophageal sphincter could result in
higher risk of late swallowing dysfunction [19]. This well
documented association between high dose to IPC or CPI
and prolonged GT dependence was also supported by two
earlier reports showing that patients were more likely to
have prolonged GT dependence and high grade dysphagia
when treated with extended-field IMRT rather than being
treated with an upper IMRT fields junctioned with an
anterior neck field. This is thought to be due to the pres-
ence of midline block in an anterior neck field to prevent
unanticipated high dose radiation to structures including
larynx, IPC, CPI and CE [20,21].
The significant dose-volume effect relationships regarding
prolonged GT dependence for IPC and CPI could be
explained by the role of the upper esophageal sphincter
(UES) in the normal swallowing process. The UES is a
functional entity that is composed of three muscles: the
IPC muscle, the CPI muscle, and the upper esophageal
muscle. The UES opens by relaxation of the three closing
muscles, traction by IPC and other muscles that attached
to the hyoid bone and thyroid cartilage, anterior move-
ment of the larynx, and pulsion of the bolus. The various
Table 3: Swallowing structure DVH parameters (median value and range) and p values for association with GT dependence
V40
(%)
V50
(%)
V60
(%)
V65
(%)
Dmax
(Gy)
Dmean
(Gy)
CE
GT > 192 d 57 (1-86) 24 (0-79) 0 (0-33) 0 (0-1) 61 (45-77) 36 (20-53)
GT   192 d 65 (17-98) 27 (0-86) 0 (0-13) 0 (0-0) 57 (44-76) 36 (21-56)
p = 2.671 p = 0.524 p = 0.173 P = 0.169 p = 0.238 p = 0.383
CPI
GT > 192 d 100 (60-100) 100 (4-100) 8 (0-100) 0 (0-100) 64 (56-78) 57 (42-69)
GT   192 d 100 (93-100) 95 (3-100) 0 (0-73) 0 (0-27) 58 (53-67) 53 (43-62)
p = 0.512 p = 0.069 p = 0.050 P = 0.062 p = 0.011 p = 0.083
IPC
GT > 192 d 100 (97-100) 100 (76-100) 81 (40-100) 42 (21-100) 74 (66-79) 64 (54-70)
GT   192 d 100 (95-100) 92 (40-100) 37 (10-84) 15 (0-60) 72 (68-77) 55 (46-68)
p = 0.367 p = 0.042 p = 0.002 P = 0.003 p = 0.057 p = 0.016
SMPC
GT > 192 d 100 (60-100) 100 (56-100) 94 (45-100) 72 (21-93) 76 (66-79) 67 (38-72)
GT   192 d 100 (84-100) 97 (70-100) 90 (25-100) 60 (0-95) 76 (70-79) 65 (50-71)
p = 0.378 p = 0.072 p = 0.063 P = 0.091 p = 0.252 p = 0.086
Abbreviation: DVH = Dose-volume histogram; GT = gastrostomy tube; SMPC = superior and middle pharyngeal constrictor; IPC = inferior 
pharyngeal constrictors; CPI = cricoid pharyngeal inlet; and CE = cervical esophagus; Dmax = maximum dose; Dmean = mean dose.Radiation Oncology 2009, 4:52 http://www.ro-journal.com/content/4/1/52
Page 7 of 10
(page number not for citation purposes)
muscles of the UES behave differently during its many
dynamic states, so that similar functions are accomplished
by different muscles. Any impairment of the CPI and IPC
could result in dysphagia. In addition, UES is considered
a high pressure zone, with the highest pressure at the
region around IPC where proprioceptive units were iden-
tified. A cause of dysphagia could also be attributed in
part to the failure of sensation and timely response to the
bolus passing through this region. The importance of IPC
and CPI is validated by our finding that patient-reported
dysphagia was highly correlated with the dose to the two
structures.
Volume-response or dose-response relationship for the average probability of having prolonged GT dependence and the vol- ume of the IPC receiving more than 6500 cGy (A), or 6000 cGy (B), or the mean dose to the IPC (C), or maximum dose to  CPI (D) Figure 2
Volume-response or dose-response relationship for the average probability of having prolonged GT depend-
ence and the volume of the IPC receiving more than 6500 cGy (A), or 6000 cGy (B), or the mean dose to the 
IPC (C), or maximum dose to CPI (D). GT = gastrostomy tube; IPC = inferior pharyngeal constrictors; CPI = cricoid pha-
ryngeal inlet. The  lines plot the mean risk; the - lines plot the estimated upper and lower limits of 95% confidence interval. 
The ♦ points depict the observed values.Radiation Oncology 2009, 4:52 http://www.ro-journal.com/content/4/1/52
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In addition to the IPC and CPI, several other anatomic
structures have been reported as dysphagia/aspiration
related with significant dose-volume relationship. These
structures include GSL and PC, with superior PC having
the strongest dose-response association [11,12]. The
importance of superior and middle PC for swallowing
after radiation therapy was also shown by Teguh et al
[14,22,23]. Although our study failed to find a significant
a correlation between GT dependence and dose to the
GSL, SMPC, or PC as a whole, this could potentially be
explained by the differences in patient characteristics. In
the above mentioned studies, only oropharynx and
nasopharynx patients were included. As such, our results
are consistent with those from Caglar et al that the mean
dose or V50 to IPC, not the superior PC, were significant
predictors for aspiration or stricture development [17].
Prolonged GT dependence is regarded by most head and
neck cancer patients as contributing to compromised
quality of life because it may cause infection and physical
discomfort, distort patient's self-esteem, and induce anxi-
ety, depression and social isolation [8]. This is of increas-
ing concern in recent years when concurrent
chemoradiation for tumor control and organ preservation
has gained widespread practice but is associated with high
rate of severe late dysphagia, including prolonged GT
dependence [5]. Multiple large randomized trials testing
intensified chemoradiation regimens reported GT rates of
about 70%, and chronic tube dependence of 10-20%
[3,6,7]. In a recent study where 95% of the chemoradia-
tion patients had prophylactic feeding tubes placed before
treatment, Caglar et al reported prolonged GT dependence
in 37% of the patients, with a median GT duration of 112
days after radiation completion [17]. Notably, we also
identified smoking as a risk factor for GT dependence. The
etiology for smoking induced dysphagia is likely multifac-
torial and related to prolonged tissue recovery secondary
to nicotine induced hypoxia, the appetite reducing effects
of nicotine, or mucosal irritation. Multiple previous works
have similarly associated smoking with higher rates of
toxicity including aspiration and esophageal stricture after
radiation therapy [24,25].
Notably, 5 out of the 12 (42%) patients with high grade
dysphagia developed upper esophageal stricture in this
study. This high incidence could have resulted from detec-
tion bias, small patient number, or most likely, patient
over-reliance on a GT which led to less swallowing and
allowing scar and stricture formation. The last possibility
is supported by results from Caudell et al who demon-
strated a trend toward an association (p = 0.09) between
GT dependence and pharyngeal stricture or stenosis [26].
Another explanation for this high incidence of stricture
among patients with high grade dysphagia could be its rel-
atation with CPI Dmax, which was significantly associated
with both high grade dysphagia and stricture formation.
In spite of this high incidence among patients with high
grade dysphagia, the overall incidence of stricture in all
patients is 12% (5/41) in our study, consistent with stric-
ture rate of 17%-37% in other studies [17,26-28].
It is important to note that this study was retrospective
with inherent limitations. First, the lack of systematic eval-
uation of some of the major end points of late dysphagia
using TNE or FEES prevented more robust analysis using
more objective endpoints. Another limitation of the study
was the relatively short follow-up with a median duration
of 15.6 months. However, most of the endpoint events
occurred less than 1 year after treatment. Given the small
number of events, we conjecture that a sub-analysis of
swallowing function assessed at greater than 1 year after
treatment would likely not change our findings. Nonethe-
less, we do acknowledge that further studies with more
comprehensive objective endpoints with prolonged fol-
low-up may be necessary to yield a more thorough evalu-
ation. This is well exemplified in a recently published
retrospective study of patients with more than 1 year fol-
low-up, where a composite of 3 objective endpoints (GT
dependence, aspiration, and pharyngoesophageal stric-
ture) were successfully used as surrogates for severe long-
term dysphagia [26].
It must also be recognized that the majority of patients in
the present study presented with oropharynx cancer, and
this fact may have biased our findings. Teguh et al, for
instance, demonstrated that patients with base of tongue
disease experienced more severe dysphagia than those
with tumors at other sites [22]. In addition to oropharynx
primary, the larynx, hypopharynx and pharyngeal wall
were also found to predispose to dysphagia more so than
other regions of the head and neck [26-29]. In contrast,
however, Logemann et al showed no differences in the fre-
quency of dysphagia across different head and neck dis-
ease sites [30], which is further supported by a large
prospective study that excluded disease site as a statisti-
cally significant factor for quality of life changes among
head and neck cancer treated with radiation therapy [31].
Lastly, we were unable to control for potentially con-
founding factors which may have also predisposed to
swallowing dysfunction including severe mucositis, pre-
treatment dysphagia and post-treatment xerostomia. We
acknowledge that the endpoints in this study, such as high
grade dysphagia and prolonged GT dependence may have
been confounded by the development of severe acute
mucositis or its consequential late effects, such as submu-
cosal edema, fibrosis, scarring, soft tissue necrosis,
impaired sensory or motor function, and loss of mucosal
compliance. This is based on the rationale that high dose
radiation to a large volume of the constrictor musclesRadiation Oncology 2009, 4:52 http://www.ro-journal.com/content/4/1/52
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(resulting in high values of V60 and V65) also results in
high dose to large volumes of mucosal surface which is
believed to lead to more severe mucositis [32-34]. How-
ever, since mucositis tends to be self-limiting and an
acute, rather than late side-effect of radiation therapy, we
believe that the potential confounding effects are mini-
mal. Furthermore, the present study demonstrated a lack
of significant association between acute mucositis and
prolonged GT dependence, which is consistent with the
findings of a dissociation between acute mucositis and
dysphagia by Mekhail et al [27] and it is supported by
recent data from Anand et al showing no correlation
between long-term dysphagia and acute mucositis (Grade
3, 4) in spite of the severe mucosities that developed in
53% of locally advanced head neck cancer patients treated
with IMRT [35]. In addition, we were unable to com-
pletely exclude the possibility of other confounding fac-
tors such as pre-treatment dysphagia or post-treatment
severe xerostomia as confounding factors. Multiple stud-
ies suggested that very few patients with newly diagnosed
head and neck cancer have severe dysphagia or aspiration
prior to definitive treatment [29,36,37]. Moreover, we
could not completely rule out xerostomia as a confound-
ing factor in spite of the reduction in the risk of this symp-
tom associated with parotid gland sparing IMRT.
Xerostomia secondary to chemotherapy or radiation ther-
apy has been suggested to significantly affect food bolus
formation and swallowing function, and contribute sig-
nificantly to dysphagia after chemoradiation [38,39]. In
particular, Teguh et al demonstrated a strong correlation
between dry mouth and sticky saliva with dysphagia-
related quality of life such as normalcy of diet and
odynophagia [22]. As a result of these potential con-
founding factors, it remains difficult to definitively estab-
lish a cause-effect association in spite of the significant
dose/volume-response relationship between some key
DVH parameters and risk of prolonged GT dependence. A
larger prospective study is required in the future to further
investigate theses associations.
Conclusion
We provided evidence that prolonged GT is correlated
with DVH parameters for patients with locally advanced
head and neck cancer treated with definitive concurrent
chemotherapy and IMRT. To minimize the risk of pro-
longed GT dependence, we currently strive to keep IPC
V65 less than 15%, IPC V60 less than 40%, and maintain
IPC Dmean less than 55 Gy, and CPI Dmax less than 60
Gy during IMRT planning in an attempt to decrease the
risk of prolonged GT dependence. It should be noted that
these guidelines are implemented on a case-by-case basis
considering such factors as tumor extent and location.
Future directions include large-scale prospective trials
aiming to assess the clinical benefits gained by applying
these dosimetric strategies. Lastly, the proposed dosimet-
ric constraints should not replace the effort of early swal-
lowing therapy and exercises which resulted in maximal
swallowing recovery in several studies [5,40].
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